 Vijaya Knight
Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunologic Deficiency Syndromes | 4 | 2023 | 64 | 2.340 |
Why?
| | Flow Cytometry | 5 | 2025 | 1155 | 2.010 |
Why?
| | Antibodies, Viral | 8 | 2022 | 601 | 1.680 |
Why?
| | Antibodies, Neutralizing | 3 | 2021 | 265 | 1.360 |
Why?
| | Cytokines | 4 | 2022 | 2013 | 1.210 |
Why?
| | Autoantibodies | 4 | 2022 | 1467 | 1.160 |
Why?
| | Laboratories | 3 | 2021 | 108 | 1.010 |
Why?
| | Immunoglobulin E | 3 | 2024 | 329 | 1.000 |
Why?
| | Immunoglobulin Class Switching | 1 | 2025 | 19 | 0.940 |
Why?
| | Immunoglobulin G | 6 | 2025 | 848 | 0.940 |
Why?
| | B-Lymphocytes | 3 | 2025 | 815 | 0.930 |
Why?
| | Immune System Diseases | 1 | 2025 | 34 | 0.920 |
Why?
| | Germinal Center | 1 | 2025 | 57 | 0.910 |
Why?
| | Antigens, Viral | 3 | 2021 | 178 | 0.900 |
Why?
| | Laboratory Proficiency Testing | 2 | 2021 | 9 | 0.880 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2024 | 86 | 0.860 |
Why?
| | Immunophenotyping | 1 | 2024 | 310 | 0.810 |
Why?
| | Killer Cells, Natural | 2 | 2024 | 427 | 0.810 |
Why?
| | Immunoassay | 3 | 2021 | 107 | 0.790 |
Why?
| | Convalescence | 1 | 2021 | 18 | 0.710 |
Why?
| | Allergy and Immunology | 1 | 2021 | 42 | 0.690 |
Why?
| | Pathology, Clinical | 1 | 2020 | 36 | 0.680 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2020 | 43 | 0.680 |
Why?
| | Blood Donors | 1 | 2021 | 96 | 0.650 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 94 | 0.650 |
Why?
| | Coronavirus Infections | 2 | 2021 | 333 | 0.610 |
Why?
| | Interferon-gamma | 3 | 2022 | 772 | 0.610 |
Why?
| | Antibody Specificity | 1 | 2018 | 184 | 0.590 |
Why?
| | Spike Glycoprotein, Coronavirus | 5 | 2022 | 108 | 0.580 |
Why?
| | Betacoronavirus | 1 | 2020 | 248 | 0.560 |
Why?
| | Societies, Medical | 1 | 2021 | 744 | 0.540 |
Why?
| | Allergens | 2 | 2024 | 385 | 0.520 |
Why?
| | Immunotherapy | 1 | 2021 | 592 | 0.520 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 339 | 0.490 |
Why?
| | Hypersensitivity | 1 | 2018 | 248 | 0.470 |
Why?
| | Sensitivity and Specificity | 5 | 2021 | 1839 | 0.470 |
Why?
| | Mycobacterium Infections, Nontuberculous | 3 | 2014 | 352 | 0.460 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 87 | 0.420 |
Why?
| | Humans | 36 | 2025 | 129266 | 0.410 |
Why?
| | Nickel | 1 | 2013 | 54 | 0.410 |
Why?
| | Food Hypersensitivity | 1 | 2015 | 176 | 0.390 |
Why?
| | Dermatitis, Allergic Contact | 1 | 2013 | 70 | 0.390 |
Why?
| | Immunoglobulins, Intravenous | 3 | 2022 | 130 | 0.380 |
Why?
| | Leukocytes, Mononuclear | 2 | 2022 | 545 | 0.380 |
Why?
| | Immunologic Factors | 1 | 2013 | 230 | 0.370 |
Why?
| | Reproducibility of Results | 5 | 2025 | 3080 | 0.350 |
Why?
| | Serologic Tests | 2 | 2021 | 52 | 0.350 |
Why?
| | Common Variable Immunodeficiency | 2 | 2021 | 26 | 0.300 |
Why?
| | Pandemics | 3 | 2021 | 1481 | 0.300 |
Why?
| | Phenotype | 3 | 2024 | 3074 | 0.230 |
Why?
| | CD56 Antigen | 1 | 2024 | 36 | 0.220 |
Why?
| | Leukocyte Common Antigens | 1 | 2024 | 82 | 0.220 |
Why?
| | Immunization, Passive | 2 | 2022 | 86 | 0.220 |
Why?
| | Lymphocytes | 2 | 2024 | 378 | 0.220 |
Why?
| | Immunologic Techniques | 1 | 2023 | 39 | 0.210 |
Why?
| | Immunoglobulin A | 1 | 2025 | 200 | 0.210 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 2024 | 97 | 0.200 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 833 | 0.200 |
Why?
| | Immunologic Memory | 1 | 2025 | 349 | 0.200 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2021 | 17 | 0.190 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2021 | 36 | 0.190 |
Why?
| | Cross Reactions | 1 | 2021 | 132 | 0.180 |
Why?
| | Male | 10 | 2025 | 63512 | 0.180 |
Why?
| | Monocytes | 1 | 2024 | 551 | 0.180 |
Why?
| | Transplantation Immunology | 1 | 2021 | 34 | 0.180 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 94 | 0.180 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 147 | 0.180 |
Why?
| | Vero Cells | 1 | 2021 | 65 | 0.180 |
Why?
| | Emergency Responders | 1 | 2021 | 35 | 0.180 |
Why?
| | Histocompatibility Testing | 1 | 2021 | 120 | 0.180 |
Why?
| | Microarray Analysis | 1 | 2021 | 117 | 0.180 |
Why?
| | RNA, Viral | 2 | 2024 | 619 | 0.180 |
Why?
| | Nucleocapsid Proteins | 1 | 2020 | 25 | 0.170 |
Why?
| | Adult | 7 | 2025 | 35495 | 0.170 |
Why?
| | Group Processes | 1 | 2021 | 57 | 0.170 |
Why?
| | Specimen Handling | 1 | 2022 | 162 | 0.170 |
Why?
| | Cholesterol Side-Chain Cleavage Enzyme | 1 | 2020 | 9 | 0.170 |
Why?
| | Coronavirus | 1 | 2021 | 43 | 0.170 |
Why?
| | Phosphorylation | 1 | 2025 | 1710 | 0.170 |
Why?
| | Pneumococcal Vaccines | 1 | 2021 | 140 | 0.170 |
Why?
| | Virtual Reality | 1 | 2021 | 52 | 0.170 |
Why?
| | Predictive Value of Tests | 1 | 2025 | 1949 | 0.160 |
Why?
| | Interleukin-13 | 1 | 2020 | 147 | 0.160 |
Why?
| | Th2 Cells | 1 | 2020 | 171 | 0.160 |
Why?
| | Female | 9 | 2025 | 68551 | 0.160 |
Why?
| | Plasma | 1 | 2020 | 205 | 0.150 |
Why?
| | Immunomodulation | 1 | 2019 | 92 | 0.150 |
Why?
| | Multiple Sclerosis | 1 | 2024 | 436 | 0.150 |
Why?
| | Peanut Hypersensitivity | 1 | 2020 | 140 | 0.150 |
Why?
| | Skin Tests | 1 | 2018 | 100 | 0.150 |
Why?
| | Phosphoproteins | 1 | 2020 | 332 | 0.150 |
Why?
| | Autoimmune Diseases | 1 | 2021 | 426 | 0.140 |
Why?
| | Animals | 5 | 2025 | 35309 | 0.140 |
Why?
| | Transfusion Reaction | 1 | 2018 | 43 | 0.140 |
Why?
| | Gamma Rays | 1 | 2018 | 54 | 0.140 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 351 | 0.140 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2715 | 0.140 |
Why?
| | Lung Diseases | 2 | 2014 | 739 | 0.140 |
Why?
| | Aged | 4 | 2025 | 22032 | 0.130 |
Why?
| | Motivation | 1 | 2021 | 546 | 0.130 |
Why?
| | Genetic Testing | 1 | 2019 | 428 | 0.130 |
Why?
| | Epoxy Resins | 1 | 2015 | 3 | 0.130 |
Why?
| | Graft vs Host Disease | 1 | 2018 | 240 | 0.120 |
Why?
| | Listeriosis | 1 | 2016 | 67 | 0.120 |
Why?
| | B-Cell Activation Factor Receptor | 1 | 2015 | 13 | 0.120 |
Why?
| | Retrospective Studies | 2 | 2025 | 14461 | 0.120 |
Why?
| | Ultraviolet Rays | 1 | 2018 | 382 | 0.120 |
Why?
| | Spirometry | 1 | 2015 | 257 | 0.120 |
Why?
| | Immune System | 1 | 2015 | 175 | 0.110 |
Why?
| | Interleukin-10 | 1 | 2016 | 300 | 0.110 |
Why?
| | Occupational Diseases | 1 | 2015 | 138 | 0.110 |
Why?
| | Algorithms | 1 | 2021 | 1613 | 0.110 |
Why?
| | Hematologic Tests | 1 | 2013 | 21 | 0.100 |
Why?
| | Pneumonia | 2 | 2015 | 616 | 0.100 |
Why?
| | Patch Tests | 1 | 2013 | 56 | 0.100 |
Why?
| | Rituximab | 1 | 2013 | 164 | 0.100 |
Why?
| | Infant, Newborn | 1 | 2024 | 5736 | 0.100 |
Why?
| | Cell Proliferation | 3 | 2018 | 2375 | 0.100 |
Why?
| | Mycobacterium avium Complex | 1 | 2013 | 88 | 0.100 |
Why?
| | Nontuberculous Mycobacteria | 1 | 2014 | 203 | 0.100 |
Why?
| | Quality Improvement | 1 | 2020 | 1095 | 0.100 |
Why?
| | Middle Aged | 4 | 2025 | 31090 | 0.100 |
Why?
| | Child, Preschool | 2 | 2024 | 10459 | 0.100 |
Why?
| | Mutation | 2 | 2022 | 3710 | 0.100 |
Why?
| | Seroepidemiologic Studies | 2 | 2023 | 156 | 0.090 |
Why?
| | Signal Transduction | 1 | 2025 | 4926 | 0.090 |
Why?
| | Transforming Growth Factor beta | 1 | 2013 | 455 | 0.090 |
Why?
| | Infant | 1 | 2024 | 8975 | 0.090 |
Why?
| | Quality of Life | 1 | 2022 | 2687 | 0.080 |
Why?
| | Inflammation | 1 | 2021 | 2737 | 0.080 |
Why?
| | Time Factors | 1 | 2021 | 6543 | 0.080 |
Why?
| | Lymphocyte Activation | 3 | 2020 | 1109 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1933 | 0.080 |
Why?
| | Child | 3 | 2024 | 20785 | 0.080 |
Why?
| | Adolescent | 2 | 2024 | 20313 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2015 | 2063 | 0.070 |
Why?
| | Colorado | 3 | 2023 | 4406 | 0.060 |
Why?
| | Cells, Cultured | 1 | 2013 | 4077 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2024 | 2703 | 0.060 |
Why?
| | Young Adult | 3 | 2020 | 12391 | 0.060 |
Why?
| | Autophagy-Related Proteins | 1 | 2022 | 42 | 0.050 |
Why?
| | Hyperplasia | 1 | 2022 | 171 | 0.050 |
Why?
| | Vesicular Transport Proteins | 1 | 2022 | 84 | 0.050 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 27 | 0.050 |
Why?
| | Aged, 80 and over | 1 | 2013 | 7055 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 154 | 0.050 |
Why?
| | World Health Organization | 1 | 2022 | 110 | 0.050 |
Why?
| | Immunity | 1 | 2022 | 138 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 232 | 0.050 |
Why?
| | Microspheres | 1 | 2021 | 124 | 0.040 |
Why?
| | Aminoglutethimide | 1 | 2020 | 5 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2022 | 276 | 0.040 |
Why?
| | Gene Knockout Techniques | 1 | 2020 | 109 | 0.040 |
Why?
| | Autophagy | 1 | 2022 | 266 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 5050 | 0.040 |
Why?
| | Furocoumarins | 1 | 2018 | 8 | 0.040 |
Why?
| | Enzyme Activation | 1 | 2020 | 812 | 0.040 |
Why?
| | NF-kappa B | 1 | 2022 | 665 | 0.040 |
Why?
| | Transfection | 1 | 2020 | 915 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2022 | 1202 | 0.030 |
Why?
| | Pilot Projects | 1 | 2021 | 1584 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2022 | 10202 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2022 | 1117 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2016 | 223 | 0.030 |
Why?
| | Adoptive Transfer | 1 | 2016 | 218 | 0.030 |
Why?
| | Blood Transfusion | 1 | 2018 | 295 | 0.030 |
Why?
| | IgA Deficiency | 1 | 2015 | 6 | 0.030 |
Why?
| | Cholangitis | 1 | 2015 | 20 | 0.030 |
Why?
| | Hepatitis | 1 | 2015 | 47 | 0.030 |
Why?
| | Listeria monocytogenes | 1 | 2016 | 123 | 0.030 |
Why?
| | Hypertrophy | 1 | 2015 | 121 | 0.030 |
Why?
| | Delayed Diagnosis | 1 | 2015 | 78 | 0.030 |
Why?
| | Granuloma | 1 | 2015 | 89 | 0.030 |
Why?
| | Sequence Alignment | 1 | 2015 | 332 | 0.030 |
Why?
| | Cell Line | 1 | 2020 | 2779 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 2016 | 333 | 0.030 |
Why?
| | Forced Expiratory Volume | 1 | 2015 | 510 | 0.030 |
Why?
| | Thymus Gland | 1 | 2015 | 308 | 0.030 |
Why?
| | Exons | 1 | 2015 | 341 | 0.030 |
Why?
| | Fibrillins | 1 | 2013 | 9 | 0.030 |
Why?
| | Marfan Syndrome | 1 | 2013 | 39 | 0.030 |
Why?
| | Lung Transplantation | 1 | 2015 | 289 | 0.030 |
Why?
| | Sinusitis | 1 | 2015 | 210 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2013 | 128 | 0.020 |
Why?
| | Occupational Exposure | 1 | 2015 | 299 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1005 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7123 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2016 | 2871 | 0.020 |
Why?
| | Kidney | 1 | 2015 | 1385 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 4057 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2013 | 3377 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 5439 | 0.020 |
Why?
| | United States | 1 | 2021 | 13826 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2015 | 5384 | 0.010 |
Why?
| | Risk Factors | 1 | 2014 | 9745 | 0.010 |
Why?
| | Mice | 1 | 2016 | 16915 | 0.010 |
Why?
|
|
Knight's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|